Table 1.
Baseline demographic and clinical characteristics of sample
| Patient characteristics | Percent | Mean (SD) | Range |
|---|---|---|---|
| Demographics | |||
| Age (years) | 67.9 (8.4) | 56–84 | |
| Sex (% female) | 19% (4/21) | ||
| Education (years) | 12.2 (3.7) | 5–18 | |
| Baseline lab measures | |||
| Systolic BP (mmHg) | 128.7 (13.9) | 108–160 | |
| Diastolic BP (mmHg) | 73.9 (9.8) | 60–90 | |
| Body mass index (kg/m2) | 24.2 (6.9) | 13.8–41.6 | |
| Blood glucose (mg/dl) | 140.6 (51.2) | 91–262 | |
| Blood urea nitrogen (mg/dl) | 18.2 (9.2) | 7–41 | |
| Creatinine (mg/dl) | 1.1 (0.3) | 0.6–1.7 | |
| Beta natriuretic peptide (pg/ml) | 205.3 (238.9) | 16.7–939.7 | |
| Medical history information | |||
| Hypertension | 67% (14/21) | ||
| Hypercholesterolemia | 71% (15/21) | ||
| Type 2 diabetes mellitus | 38% (8/21) | ||
| History of smoking | 67% (14/21) | ||
| Prior myocardial infarction | 52% (11/21) | ||
| History of atrial fibrillation | 33% (7/21) | ||
| Percutaneous coronary intervention | 52% (11/21) | ||
| Coronary artery bypass surgery | 14% (3/21) | ||
| Previous ICD | 10% (2/21) | ||
| Valve surgery | 5% (1/21) | ||
| Heart failure etiology | |||
| Ischemic | 48% (10/21) | ||
| Nonischemic | 52% (11/21) | ||
| NYHA Heart Failure Class | |||
| Class II | 55% (11/21) | ||
| Class III and IV* | 45% (9/21) | ||
| Medications | |||
| Beta blockers | 95% (20/21) | ||
| Aspirin/antithrombotics | 81% (17/21) | ||
| Lipid lowering agents | 76% (16/21) | ||
| ACE inhibitors | 76% (16/21) | ||
| Diuretics | 67% (14/21) | ||
| Digoxin | 43% (9/21) | ||
| Hypoglycemics | 33% (7/21) | ||
| Antidepressants/antianxiety | 33% (7/21) | ||
| Vasodilators | 29% (6/21) | ||
*
Notes: Class III and IV were grouped for analytic purposes because 1 person was Class IV.